Horizon’s science base draws upon a 20 year heritage in oncology research, translational medicine and genome-editing. This heritage is the basis of Horizon’s expertise in translational genomics that has led to the development of GENESIS™ a proprietary genome-editing platform based on the unique ability of rAAV vectors to stimulate homologous recombination. By exoliting a cell’s natural means of repairing its own DNA in an error-free manner, rAAV GENESIS™ enables the precise insertion, deletion, substition of a desired DNA sequence into any endogenous gene loci in any mammalian cell.